Philogen SpA
MIL:PHIL
Intrinsic Value
Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. [ Read More ]
The intrinsic value of one PHIL stock under the Base Case scenario is 24.1 EUR. Compared to the current market price of 17.9 EUR, Philogen SpA is Undervalued by 26%.
Valuation Backtest
Philogen SpA
Run backtest to discover the historical profit from buying and selling PHIL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Philogen SpA
Current Assets | 89.2m |
Cash & Short-Term Investments | 75.3m |
Receivables | 11.4m |
Other Current Assets | 2.5m |
Non-Current Assets | 30m |
PP&E | 25.9m |
Intangibles | 1.2m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 12.7m |
Accounts Payable | 7.8m |
Accrued Liabilities | 1.2m |
Other Current Liabilities | 3.7m |
Non-Current Liabilities | 16m |
Long-Term Debt | 13m |
Other Non-Current Liabilities | 2.9m |
Earnings Waterfall
Philogen SpA
Revenue
|
23.1m
EUR
|
Cost of Revenue
|
-13.9m
EUR
|
Gross Profit
|
9.3m
EUR
|
Operating Expenses
|
-18.1m
EUR
|
Operating Income
|
-8.8m
EUR
|
Other Expenses
|
2.7m
EUR
|
Net Income
|
-6.2m
EUR
|
Free Cash Flow Analysis
Philogen SpA
PHIL Profitability Score
Profitability Due Diligence
Philogen SpA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Philogen SpA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
PHIL Solvency Score
Solvency Due Diligence
Philogen SpA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Philogen SpA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHIL Price Targets Summary
Philogen SpA
According to Wall Street analysts, the average 1-year price target for PHIL is 23.97 EUR with a low forecast of 22.22 EUR and a high forecast of 26.25 EUR.
Shareholder Return
PHIL Price
Philogen SpA
Average Annual Return | -8.29% |
Standard Deviation of Annual Returns | 6.84% |
Max Drawdown | -25% |
Market Capitalization | 519m EUR |
Shares Outstanding | 28 992 031 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 135 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The firm's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
Contact
IPO
Employees
Officers
The intrinsic value of one PHIL stock under the Base Case scenario is 24.1 EUR.
Compared to the current market price of 17.9 EUR, Philogen SpA is Undervalued by 26%.